Recent Pfizer Press Releases

  • 6/13/17 9:00 am EDT

    Pfizer and Parents Magazine Team Up to Educate Parents About a Serious Disease That Can Put a Child’s Life at Risk

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE), in partnership with Parents magazine (NYSE:MDP), announced today the results of a national survey of more than 2,000 new and expectant parents assessing their knowledge of childhood infectious diseases, such as measles, whooping cough and invasive pneumococcal disease (IPD), and the measures parents can take to help prevent them. Conducted online by Harris Poll, the survey found that parents were leastmore...
  • 6/13/17 8:00 am EDT
    • Global Phase 3 program is studying potential new treatment option for millions of people living with chronic pain associated with osteoarthritis and chronic low back pain
    • Acts in a different manner than opioids and other analgesics
    NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor (NGF). It is the first NGF inhibitor tomore...
  • 6/10/17 1:00 pm EDT

    Ertugliflozin as Add-on to Metformin or in Initial Co-administration with Sitagliptin Showed Significant A1C Reductions in Adults with Type 2 Diabetes

    KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS MET and VERTIS SITA) of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes, met their primary endpoints. In the studies, both doses of ertugliflozin tested (5 mg and 15 mg daily) achieved statisticallymore...
  • 6/9/17 8:00 am EDT

    - Amendment accelerates anticipated PROSPER top-line results by two years -

    - Target sample size reduced to approximately 1,440 patients and estimated primary completion date is June 2017 -

    TOKYO & NEW YORK--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE:PFE) announced today the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of XTANDI® (enzalutamide) in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). The primary endpoint remains the same:more...
  • 6/7/17 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017 at 8:00 a.m. Pacific Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registering for the webcastmore...
  • 6/6/17 8:00 am EDT

    —Tafamidis, An Investigational Medicine for TTR-CM a Rare, Progressive and Fatal Disease, is Currently in Phase 3 Development—

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to tafamidis, the company’s investigational treatment for transthyretin cardiomyopathy (TTR-CM). This rare disease is associated with progressive heart failure and is universally fatal.1,2,3 Currently in Phase 3 clinical development for TTR-CM, tafamidis is being evaluated for its potential to reduce mortality and cardiovascularmore...
  • 6/3/17 4:30 pm EDT

    Phase 3 EMBRACA trial of talazoparib in advanced gBRCA+ breast cancer now fully enrolled

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced Phase 2 data showing that its investigational, dual-mechanism poly ADP ribose polymerase (PARP) inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline (inherited) BRCA1/2-positive (gBRCA+) advanced breast cancer. Results from the Phase 2 ABRAZO trial were presented during an oral session at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicagomore...
  • 5/31/17 8:30 am EDT

    Applications seek to expand approved use of SUTENT based on data from the Phase 3 S-TRAC trial

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that a supplemental New Drug Application (sNDA) for SUTENT® (sunitinib) has been accepted for filing by the U.S. Food and Drug Administration (FDA). If approved, the sNDA would expand the approved use of SUTENT to include use as an adjuvant treatment in adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancer-containing kidney). In addition,more...
  • 5/30/17 10:00 am EDT

    Meningococcal Group B (MenB) is Responsible for 60 Percent of Meningococcal Disease Cases in Adolescents and Young Adults in Europe 1

    TRUMENBA Approved in Europe with Option for a Two- or Three-Dose Schedule

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved TRUMENBA® (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older. Adolescents and young adults are a critical demographic for vaccination against MenB due to inherent environmental and social risk factors such as close-quartered living andmore...
  • 5/25/17 1:16 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company’s proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by a U.S. FDA Advisory Committee. The Committee’s favorable recommendation was based on itsmore...